Axsome Therapeutics (NASDAQ:AXSM) Reports Strong Q1 Revenue Growth and Key Drug Approval Amid Insider Share Sale
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAxsome Therapeutics, Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









